IDF, WHF and UICC join forces

The International Diabetes Federation (IDF), International Union Against Cancer (UICC) and World Heart Federation (WHF) have issued a joint statement that calls on the international community to address urgently the epidemic of non-communicable diseases (NCDs), responsible for 35 million deaths a year. The statement demands a substantial increase in funding for NCDs and greater availability of essential medicines, among other urgent responses, in a way to accelerate achievement of the health Millennium Development Goals.

Public health experts are concerned about the impact of the global economic crisis and warn that the emerging epidemic of NCDs is threatening to overwhelm healthcare systems worldwide unless action is taken. Cardiovascular disease, diabetes, cancer and chronic respiratory diseases cause 60% of all deaths worldwide, with four in every five of these deaths occurring in low- and middle-income countries. NCDs are an under-appreciated cause of poverty and now present a serious barrier to economic development. They are estimated to reduce gross domestic product (GDP) by up to 5% in many low- and middle-income countries, dealing a double blow to fragile economies struggling in the global recession.

Professor Pekka Puska, President of the World Heart Federation states: “We can no longer ignore the burden that cardiovascular disease, together with the other NCDs including diabetes, cancer and chronic respiratory diseases, is placing on countries that are least equipped to deal with them. We urgently call on the international community to ensure that the funding models applied to infectious diseases, such as HIV/AIDS, TB and malaria are expanded to stop the spiralling death rates from NCDs before the most vulnerable are pushed further into the poverty trap.”

NCDs impact on the world

IDF, WHF and UICC are united by their concern with the consequences of physical inactivity, tobacco use and poor diet, three avoidable risk factors that contribute significantly to the NCDs responsible for 60% of global mortality.

Diabetes is a leading cause of blindness, kidney failure, heart attack, stroke and amputation. The number of people living with diabetes has increased considerably over the past 30 years. In 1985, an estimated 30 million people worldwide had diabetes. A little over a decade later, the figure had risen to over 150 million. Today, according to IDF figures, it exceeds 250 million. A further 300 million are at high risk of developing diabetes. Unless action is taken to implement effective prevention and control programmes, IDF predicts that the total number of people with diabetes will reach 380 million by 2025.

Cardiovascular disease (CVD) is the leading cause of death worldwide. An estimated 17.2 million people die from CVD each year, and that toll could increase to almost 20 million by 2015. The incidence of deaths attributable to CVD continues to rise sharply, accounting for 30% of all deaths globally. Around 80% of these deaths and 87% of related disabilities occur in low- and middle-income countries. Cardiovascular disease affects the heart or blood vessels and includes heart disease, stroke and high blood pressure.

Cancer is the second leading cause of death worldwide. More than 11 million new cases are diagnosed each year, and about 8 million people die from cancer - over 70% of them in low- and middle-income countries. On current trends, 15.5 million people will be diagnosed with cancer in 2030, and about 12 million people will die from the disease. Yet, we have more knowledge than ever before on how to bring cancer under control. About one-third (30-40%) of all cancers can be prevented, a further third can be cured (given early diagnosis and treatment), and effective palliative care can be provided to patients.

In its 2009-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases, the World Health Organization identifies international partnerships as paramount in the global struggle against NCDS. WHO calls for concerted action on a global scale and identifies a key role for non-governmental organizations. IDF, WHF and UICC have taken up this call. Combined, the three organizations represent the interests of 730 member organizations in over 170 countries. They have joined forces to create a powerful voice for change and urge the international community to take action in the face of the NCD epidemic.

Professor David Hill, President of the International Union against Cancer states: “Now, more than ever, we need to join efforts to give cancer and the other NCDs the priority they deserve. The advantages that stand to be gained from the strength of strategic international partnerships, such as the one between our three organizations, will contribute towards a more effective global response to NCDs.”

Call for Action

The joint statement issued today in Geneva was timed to coincide with the meeting of the World Health Assembly. The organizations highlighted their support for the WHO Action Plan and call for the international community to:

1. Ensure the availability of essential medicines for people living with NCDs in low- and middle- income countries

2. Immediately and substantially increase financing for NCDs
3. Integrate NCD prevention into national health systems and the global development agenda
4. Create a Special Envoy of the UN Secretary-General for NCDs
5. Support a UN General Assembly Special Session on NCDs

WHO has shown that simple, cost-effective solutions exist to take on the burgeoning epidemic of NCDs. If the international community acts now, hundreds of millions of lives could be saved and the quality of life improved for millions more. Such action would bring the international community closer to achieving the UN Millennium Development Goals. Failure to act will have a detrimental effect on healthcare systems and economies worldwide. Governments who invest in prevention now will be spared the overwhelming costs of chronic care later.

Professor Martin Silink, President of the International Diabetes Federation explains: “the world has not previously had to cope with an epidemic of NCDs. Health systems will need to adapt fast to mobilize new and existing resources to tackle the epidemic through prevention and education. The majority of people with non-communicable diseases like diabetes, cardiovascular disease and cancer are responsible for most of their own care most of the time. Health systems will need to support the role of people with NCDs and see them as part of the solution.”

Source:
Kerrita McClaughlyn

International Diabetes Federation

The Multiple Myeloma Research Foundation (MMRF) has announced a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma by whole genome sequencing of individual patient tumors. The MMRF will provide both patient samples for analysis as well as funding for the project. All data from this collaboration will be put in the public domain.

“We are delighted to work with the MMRF, which has been a visionary organization in accelerating cancer research for the sake of patients and their families,” said Eric S. Lander, PhD, Director of the Broad Institute. “Through our work together on this critical pilot project in whole cancer genome sequencing, we hope not only to advance clinical progress for multiple myeloma, but to build knowledge and technical capabilities that can be applied to many other human cancers.”

“Three years ago, the MMRF launched a partnership with the Broad Institute and the Translational Genomics Research Institute - the Multiple Myeloma Genomics Initiative - a comprehensive genome mapping program to identity new targets and eventually new therapies for this incurable disease,” said Kathy Giusti, Founder and CEO of the MMRF, and a multiple myeloma patient. “As part of that larger effort, we are confident that this groundbreaking research will accelerate the development of next-generation treatments to extend the lives of multiple myeloma patients. Additionally, we believe that this work will not only ultimately pave the way to a cure for patients with multiple myeloma, but will benefit patients with other types of cancer.”

The creation of comprehensive catalogs of all commonly occurring cancer mutations is a current approach of several national and international consortia, including The Cancer Genome Atlas (TCGA) led by the US National Institutes of Health and the International Cancer Genome Consortium (ICGC), to understand major tumor types such as leukemia, lung cancer, glioblastoma and others. To date, only a handful of whole cancer genomes have been sequenced and only one has been published.

“The few cancer genomes sequenced to date have been informative, but we need many more to transform cancer research and ultimately cancer therapy,” said Stacey Gabriel, PhD, Co-Director of the Broad Institute’s Genome Sequencing and Analysis Program. “This exciting collaboration with the MMRF will advance these goals by contributing public domain data.”

Source:
Nicole Davis

Broad Institute of MIT and Harvard

A new sensor device allowing doctors to receive data on the precise amount of radiation being delivered to tumors and surrounding tissue is now being offered at Maury regional Medical Cancer Center. Maury Regional Medical Center is the first in Tennessee to use the technology called DVS® (Dose Verification System) for breast cancer patients undergoing radiation treatment.

John P. W. Brown, M.D., surgeon, inserts a device that is as small as the length of a dime and can be inserted inside the patient’s tumor bed in less than 15 minutes. After each radiation treatment, the DVS® provides the radiation oncologists (Dr. Michael Sattasiri and Dr. Joel Kochanski) with a measurement of the actual amount of radiation hitting the target where the malignant tumor was removed. This allows Dr. Sattasiri and Dr. Kochanski to make any necessary adjustments to the prescribed dose during the radiation therapy treatment course, making it more precise. The DVS® sensor wirelessly transmits data to the physician immediately following each radiation treatment.

Increasing cancer cure rates and decreasing complications associated with radiation therapy are the goals physicians strive for when treating their patients. DVS® is the first wireless, implantable radiation sensor available in the United States to assist physicians in obtaining these goals. The sensor provides data on the precise amount of radiation being delivered to the tumor and surrounding normal tissue.

“Patients with breast cancer are well educated and often spend considerable amounts of time researching new treatment options to help them in their battle with cancer. They also place tremendous value on being treated with the most up to date technologies. We are excited to be the first facility in Tennessee to offer this technology to patients with breast cancer,” says John Brown, M.D., breast surgeon at Maury Regional Medical Center. “Traditional radiation therapies rely on knowing the exact location of the tumor, but provide no guidance on quantifying the actual dose being delivered to the tumor. DVS® provides an unprecedented level of precision to physicians and added reassurance to breast and prostate cancer patients,” he adds.

Developed by Sicel Technologies, Inc., the DVS® sensors are implanted during a minimally invasive procedure and gather data on the amount of radiation being delivered to the tumor and normal tissue. Wireless technology transmits the radiation dose information to a hand-held monitor during each of the daily treatments, enabling doctors to verify that the patient is receiving the prescribed dose. If a dose deviation is detected, the treatment plan can be modified and corrected for each individual patient. Accurate delivery of the appropriate dose of radiation is critical for tumor control and cure.

“Maury Regional Medical Center is committed to bringing patients innovative new technologies that can have a positive effect on their end results. We provide many options to our patients and are now screening breast cancer patients to receive this breakthrough technology,” says Dr. Brown, who inserted the first DVS® sensor at Maury Regional Medical Center.

Source
Maury Regional Medical Center